Agenus INC 10-Q quarterly reports

Agenus Inc. announced its first-quarter 2026 financial results, highlighting a substantial increase in cash reserves driven by strategic collaborations and asset sales, alongside a significant reduction in operating expenses.

Agenus Inc. reported a net income of $63.86 million for Q3 2025, driven by a significant gain from the deconsolidation of MiNK Therapeutics and reduced operating expenses, despite ongoing liquidity concerns.

Agenus Inc. reported a reduced net loss for Q2 2025 but faces substantial doubt about its ability to continue as a going concern, despite a pending asset sale and equity investment.

Agenus Inc. announces its Q1 2025 financial results, highlighting a net loss, decreased revenue, and substantial doubt about its ability to continue as a going concern.

Agenus Inc. reported its third quarter 2024 results, highlighting increased non-cash royalty revenue but also significant operating losses and concerns about its ability to continue as a going concern.

Agenus Inc. reports a net loss of $115.1 million for the six months ended June 30, 2024, while highlighting strategic partnerships and pipeline advancements.

Agenus Inc. reported a net loss of $61.9 million for the first quarter of 2024, while highlighting progress in its clinical programs and a new $75 million royalty monetization deal.